Biomea Fusion Launches Public Offering of Common Stock and Warrants
Biomea Fusion, Inc., a clinical-stage company focused on diabetes and obesity treatments, has initiated an underwritten public offering of its common stock and accompanying warrants. Jefferies is acting as the sole book-running manager for this offering, which is contingent on market conditions and other uncertainties.
The company's objective is evident: provide transformative treatments for patients grappling with diabetes, obesity, and related conditions. Jayson Bedford, the Managing Director of Investor Relations and Corporate Development, spearheads this endeavor. Biomea's latest SEC filings, including its annual report on Form 10-K and subsequent quarterly reports on Form 10-Q, outline the risks and uncertainties associated with this mission.
The offering includes an option for underwriters to purchase an additional 15% of shares and/or warrants. A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC and made accessible through Jefferies LLC. This press release contains forward-looking statements, including those about the proposed offering and Biomea's research, development, and regulatory plans. These statements should be evaluated in the context of various factors that could cause actual results to differ materially.
Biomea Fusion, Inc. is offering shares of its common stock and accompanying warrants to the public, with Jefferies serving as the sole book-running manager. The offering is subject to market and other conditions, and its completion is uncertain. Interested parties can find more information in the preliminary prospectus supplement and accompanying prospectus to be filed with the SEC.
